Study guide

3.9 Neuromuscular Reversal & Vasoactive Airway Support

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

3.9 Neuromuscular Reversal & Vasoactive Airway Support

Key Takeaways Explain This Topic AI

Sugammadex provides rapid encapsulation and reversal of aminosteroid neuromuscular blocking agents (Rocuronium > Vecuronium); a dose of 16 mg/kg allows immediate reversal after 1.2 mg/kg Rocuronium RSI in rescue situations.

Neostigmine relies on acetylcholinesterase inhibition and must be co-administered with an anticholinergic (Glycopyrrolate or Atropine) to prevent life-threatening muscarinic bradycardia and bronchorrhea.

Push-dose pressors (Phenylephrine 50-200 mcg or Epinephrine 5-20 mcg) treat acute peri-intubation hypotension resulting from loss of sympathetic tone and positive pressure ventilation.

Hemodynamic optimization before intubation using volume loading and pressors prevents peri-intubation cardiac arrest ('HOP' kill spikes: Hypotension, Hypoxemia, pH/Acidosis).

Last updated: July 2026

3.9 Neuromuscular Reversal & Vasoactive Airway Support

Emergency Rapid Sequence Induction (RSI) induces profound physiological stress. Transport clinicians must manage neuromuscular blockade reversal during emergency airway failures and administer push-dose vasopressors to prevent post-intubation hemodynamic collapse.

1. Neuromuscular Blockade Reversal Agents

Reversal of non-depolarizing neuromuscular blocking agents (NMBAs) is indicated when a patient cannot be intubated or ventilated, or when extubation criteria are met following transport. NEUROMUSCULAR REVERSAL MECHANISMS

Sugammadex Encapsulation: Neostigmine AChE Inhibition:

  • +-------------+ +-----------------------+
  • | Sugammadex | | Neostigmine Blocks |
  • | Ring | | Acetylcholinesterase |
  • | +-------+ | +-----------+-----------+
  • | | Rocur | | |
  • | +-------+ | [ Increased Synaptic ACh ]
  • +-------------+ |
  • (Inactivated Complex Excreted) [ Competes with NMBD at NMJ ]
  • +
  • [ MUST Add Glycopyrrolate ]
  • (Prevents Severe Muscarinic Effects)
  • A. Sugammadex (Bridion)

Sugammadex is a modified γ \gamma γ -cyclodextrin designed to selectively encapsulate aminosteroid NMBAs ( Rocuronium and Vecuronium ).

Mechanism of Action: Forms a lipophilic core complex with free Rocuronium in plasma at a 1 : 1 1:1 1 : 1 ratio, rapidly lowering free drug concentration and driving the NMBA away from the neuromuscular junction (NMJ) back into plasma.

Dosing Tiers:

2 mg/kg 2 \text{ mg/kg} 2 mg/kg IV: Routine reversal of shallow blockade (reappearance of T 2 T_2 T 2 ​ twitch on Train-of-Four [TOF]).

4 mg/kg 4 \text{ mg/kg} 4 mg/kg IV: Reversal of deep blockade ( 1 − 2 1-2 1 − 2 post-tetanic counts [PTC] with zero TOF twitches).

16 mg/kg 16 \text{ mg/kg} 16 mg/kg IV: Immediate emergency rescue reversal following high-dose Rocuronium ( 1.2 mg/kg 1.2 \text{ mg/kg} 1.2 mg/kg ) RSI in a "Cannot Intubate, Cannot Ventilate" scenario. Reverses blockade within 3 minutes 3 \text{ minutes} 3 minutes .

Drug Interactions & Warnings:

Binds to oral contraceptives, decreasing their efficacy (equivalent to missing 1 daily dose; patients must use barrier contraception for 7 days).

Ineffective against Succinylcholine or benzylisoquinoliniums (Cisatracurium, Atracurium).

B. Neostigmine + Anticholinergic Co-Administration

Neostigmine is a traditional acetylcholinesterase (AChE) inhibitor.

Mechanism of Action: Inhibits breakdown of acetylcholine (ACh) in the synaptic cleft, elevating ACh concentration to outcompete non-depolarizing NMBAs at nicotinic receptors.

Dosing: Neostigmine 0.03 − 0.07 mg/kg 0.03 - 0.07 \text{ mg/kg} 0.03 − 0.07 mg/kg IV (maximum single dose 5 mg 5 \text{ mg} 5 mg ). Requires at least partial spontaneous recovery ( T 2 T_2 T 2 ​ visible on TOF); ineffective for immediate rescue from deep paralysis.

Mandatory Anticholinergic Co-Administration: Acetylcholinesterase inhibition elevates ACh at both nicotinic and muscarinic receptors, causing severe bradycardia, AV block, bronchospasm, hyper-salivation, and bronchorrhea. Neostigmine must always be co-administered with an anticholinergic:

Anticholinergic Partner Standard Dosing Ratio Onset Matching Central Nervous System Effects

Glycopyrrolate 0.2 mg 0.2 \text{ mg} 0.2 mg Glycopyrrolate per 1.0 mg 1.0 \text{ mg} 1.0 mg Neostigmine Matches Neostigmine onset ( 2 − 3 min 2-3 \text{ min} 2 − 3 min ) perfectly Does not cross blood-brain barrier (no sedation/confusion)

Atropine 0.4 mg 0.4 \text{ mg} 0.4 mg Atropine per 1.0 mg 1.0 \text{ mg} 1.0 mg Neostigmine Faster onset than Neostigmine ( 1 min 1 \text{ min} 1 min ) Crosses blood-brain barrier (risk of central anticholinergic syndrome)

2. Peri-Intubation Hemodynamic Optimization & Push-Dose Pressors

Induction and positive pressure ventilation frequently trigger severe hypotension. Peri-intubation cardiac arrest occurs in up to 2 − 4 % 2-4\% 2 − 4% of emergency intubations, driven primarily by profound post-induction hypotension. PATHOPHYSIOLOGY OF POST-INTUBATION HYPOTENSION

  • Induction Agents (Propofol/Midazolam) ---> Vasodilation + Sympatholysis
  • |
  • Positive Pressure Ventilation ---> High Intra-thoracic Pressure
  • |
  • Decreased Venous Return (Preload) ---> DROPPED CARDIAC OUTPUT
  • |
  • [ SEVERE HYPOTENSION ]
  • Push-Dose Vasopressor Protocols

Push-dose pressors provide immediate temporizing vasopressor support during the peri-intubation window while continuous infusions are prepared. PUSH-DOSE PRESSOR MIXING GUIDE

Phenylephrine (100 mcg/mL): Epinephrine (10 mcg/mL):

  • 1. Take 1 mL Phenylephrine (10 mg/mL) 1. Take 1 mL Epi 1:10,000 (100 mcg/mL)
  • 2. Inject into 100 mL NS bag 2. Draw up into syringe with 9 mL NS
  • 3. Yields 100 mcg/mL 3. Yields 10 mcg/mL ("Dirty Epi")
  • 4. Dose: 50-200 mcg (0.5-2 mL) 4. Dose: 5-20 mcg (0.5-2 mL)
  • A. Push-Dose Phenylephrine

Pharmacology: Pure α 1 \alpha_1 α 1 ​ -adrenergic receptor agonist causing arterial vasoconstriction and increased Systemic Vascular Resistance (SVR).

Mixing Protocol: Draw 1 mL 1 \text{ mL} 1 mL of Phenylephrine ( 10 mg/mL = 10 , 000 mcg 10 \text{ mg/mL} = 10,000 \text{ mcg} 10 mg/mL = 10 , 000 mcg ) and inject into a 100 mL 100 \text{ mL} 100 mL bag of Normal Saline. Concentration = 100 mcg/mL = 100 \text{ mcg/mL} = 100 mcg/mL .

Dosing: Administer 50 − 200 mcg 50 - 200 \text{ mcg} 50 − 200 mcg ( 0.5 − 2.0 mL 0.5 - 2.0 \text{ mL} 0.5 − 2.0 mL ) IV/IO every 2 − 5 minutes 2-5 \text{ minutes} 2 − 5 minutes .

Onset & Duration: Onset 1 minute 1 \text{ minute} 1 minute ; duration 10 − 20 minutes 10-20 \text{ minutes} 10 − 20 minutes .

Best Clinical Indication: Pure vasodilatory hypotension with normal or elevated baseline heart rate (causes reflex bradycardia).

B. Push-Dose Epinephrine

Pharmacology: Direct α 1 \alpha_1 α 1 ​ , β 1 \beta_1 β 1 ​ , and β 2 \beta_2 β 2 ​ -agonist providing potent vasoconstriction, inotropy, chronotropy, and bronchodilation.

Mixing Protocol: Take 1 mL 1 \text{ mL} 1 mL of Epinephrine 1 : 10 , 000 1:10,000 1 : 10 , 000 ( 100 mcg/mL 100 \text{ mcg/mL} 100 mcg/mL ) in a syringe and add 9 mL 9 \text{ mL} 9 mL of Normal Saline. Concentration = 10 mcg/mL = 10 \text{ mcg/mL} = 10 mcg/mL .

Dosing: Administer 5 − 20 mcg 5 - 20 \text{ mcg} 5 − 20 mcg ( 0.5 − 2.0 mL 0.5 - 2.0 \text{ mL} 0.5 − 2.0 mL ) IV/IO every 2 − 5 minutes 2-5 \text{ minutes} 2 − 5 minutes .

Onset & Duration: Onset 1 minute 1 \text{ minute} 1 minute ; duration 5 − 10 minutes 5-10 \text{ minutes} 5 − 10 minutes .

Best Clinical Indication: Post-induction hypotension accompanied by bradycardia, profound myocardial depression, or septic/anaphylactic shock.

3. Resuscitation Prior to Intubation

To prevent the "HOP" kill spikes ( H ypotension, O xygenation deficit, P H/Acidosis) during RSI:

Pre-Intubation Volume Loading: Administer 500 − 1 , 000 mL 500 - 1,000 \text{ mL} 500 − 1 , 000 mL crystalloid or blood products prior to induction in hypovolemic patients.

Hemodynamically Neutral Induction: Utilize Ketamine ( 1.5 − 2.0 mg/kg 1.5-2.0 \text{ mg/kg} 1.5 − 2.0 mg/kg IV) or Etomidate ( 0.3 mg/kg 0.3 \text{ mg/kg} 0.3 mg/kg IV) rather than Propofol ( 1.5 − 2.5 mg/kg 1.5-2.5 \text{ mg/kg} 1.5 − 2.5 mg/kg ) or Midazolam ( 0.1 − 0.2 mg/kg 0.1-0.2 \text{ mg/kg} 0.1 − 0.2 mg/kg ), which cause severe venodilation and myocardial depression.